Payment overview · 2025
General Payments
$6,555.40
295 reported records · 38 companies
Healthcare provider profile · identity verified
Amir Shokrae, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ORANGE, CA · NPI 1306934112
Verified facts
What the public records show
CMS Open Payments records show Amir Shokrae, M.D. received $6,555.40 in general payments during 2025 across 295 reported records.
ABBVIE INC. accounted for 11.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Gamunex-C, Ingrezza, Qulipta, Xcopri.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rytary by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Privigen by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gamunex-C by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ingrezza by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Gammagard Liquid by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $728.10 | 11.1% | 30 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $628.71 | 9.6% | 24 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $602.43 | 9.2% | 19 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $353.77 | 5.4% | 14 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $317.67 | 4.8% | 11 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $304.26 | 4.6% | 11 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $269.57 | 4.1% | 15 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $251.51 | 3.8% | 10 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$250.76 | 3.8% | 16 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $233.29 | 3.6% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $216.79 | 3.3% | 17 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $203.34 | 3.1% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $191.65 | 2.9% | 11 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $190.67 | 2.9% | 8 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $186.12 | 2.8% | 8 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $176.77 | 2.7% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $165.77 | 2.5% | 11 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $161.41 | 2.5% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $141.80 | 2.2% | 10 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $138.68 | 2.1% | 7 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $100.62 | 1.5% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $98.77 | 1.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $93.84 | 1.4% | 4 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $79.29 | 1.2% | 4 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $58.20 | 0.9% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $50.90 | 0.8% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $50.50 | 0.8% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $43.41 | 0.7% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $40.59 | 0.6% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $35.72 | 0.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.69 | 0.5% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $34.41 | 0.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $34.09 | 0.5% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.06 | 0.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.21 | 0.3% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $16.12 | 0.2% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$15.12 | 0.2% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $14.79 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $6,555.40 | 295 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $468.54 | 15 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $414.54 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $379.63 | 14 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $377.46 | 16 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $353.77 | 14 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $336.08 | 15 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $332.99 | 12 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $317.67 | 11 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $269.57 | 15 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $251.51 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $249.56 | 9 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $233.29 | 11 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $217.64 | 8 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $216.79 | 17 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $203.34 | 9 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $186.12 | 8 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $176.77 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $176.51 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $161.53 | 9 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $148.90 | 10 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $141.80 | 10 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $141.13 | 5 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $133.89 | 4 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc., PFIZER INC. | $111.88 | 4 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $100.62 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $86.12 | 4 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $71.17 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $71.17 | 3 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $64.67 | 2 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $58.20 | 2 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $57.52 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $43.41 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $40.59 | 2 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $40.59 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $35.72 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $34.69 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $34.09 | 2 | 2025 |
Source payment records
|
|||||
| Enspryng Normalized: enspryng |
Biological | Genentech USA, Inc. | $32.16 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $27.48 | 1 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| REYVOW Normalized: reyvow |
Drug | Lilly USA, LLC | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| VNS Therapy Normalized: vns therapy |
Device | LivaNova USA, Inc. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| AGAMREE Normalized: agamree |
Drug | CATALYST PHARMACEUTICALS, INC. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| NOURIANZ Normalized: nourianz |
Drug | KYOWA KIRIN, INC. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 636 | 202 |
| Donepezil Hcl | Donepezil Hcl | 502 | 173 |
| Gabapentin | Gabapentin | 468 | 170 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 155 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 53 |
| Levetiracetam | Levetiracetam | 148 | 42 |
| Pregabalin | Pregabalin | 127 | 39 |
| Alprazolam | Alprazolam | 124 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 17 |
| Sertraline Hcl | Sertraline Hcl | 103 | 36 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 97 | 26 |
| Topiramate | Topiramate | 96 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | 29 |
| Memantine Hcl Er | Memantine Hcl | 89 | 26 |
| Propranolol Hcl | Propranolol Hcl | 84 | 32 |
| Amantadine | Amantadine Hcl | 82 | 27 |
| Lorazepam | Lorazepam | 80 | 23 |
| Primidone | Primidone | 79 | 26 |
| Clonazepam | Clonazepam | 72 | 21 |
| Rivastigmine | Rivastigmine Tartrate | 67 | 21 |
| Mirtazapine | Mirtazapine | 65 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 24 |
| Carbamazepine Er | Carbamazepine | 62 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 59 | 14 |
| Lamotrigine | Lamotrigine | 57 | 15 |
| Divalproex Sodium Er | Divalproex Sodium | 53 | 14 |
| Baclofen | Baclofen | 50 | 18 |
| Bupropion Xl | Bupropion Hcl | 48 | suppressed |
| Lacosamide | Lacosamide | 48 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 48 | 14 |
| Aripiprazole | Aripiprazole | 47 | 15 |
| Buspirone Hcl | Buspirone Hcl | 47 | 11 |
| Zonisamide | Zonisamide | 47 | 12 |
| Diazepam | Diazepam | 44 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 19 |
| Tramadol Hcl | Tramadol Hcl | 41 | 11 |
| Modafinil | Modafinil | 40 | 14 |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 38 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 38 | 17 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 35 | 12 |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 33 | suppressed |
| Carbamazepine | Carbamazepine | 32 | 11 |
| Folic Acid | Folic Acid | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Rivastigmine | Rivastigmine | 25 | suppressed |
| Rytary | Carbidopa/Levodopa | 25 | suppressed |
| Briviact | Brivaracetam | 24 | suppressed |
| Entacapone | Entacapone | 21 | suppressed |
| Methadone Hcl | Methadone Hcl | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Armodafinil | Armodafinil | 19 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 16 | suppressed |
| Copaxone | Glatiramer Acetate | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 14 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 14 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 14 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Lamotrigine Er | Lamotrigine | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Xcopri | Cenobamate | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,555.40 · 295 records | ABBVIE INC. | AGAMREE, AMYVID, AUSTEDO XR, BOTOX, BRIUMVI, Bafiertam, Briviact, CREXONT, Dysport, EMGALITY, Enspryng, FIRDAPSE, Gamunex-C, HYQVIA, Hizentra, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, LUMRYZ, NOURIANZ, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, REYVOW, Radicava, Rystiggo, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VNS Therapy, VRAYLAR, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, WAKIX, XCOPRI, Xeomin, ZAVZPRET, ZEPOSIA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error